Kansas City, KS1 Active Studies

Myeloproliferative Neoplasms Clinical Trials in Kansas City, KS

Find 1 actively recruiting myeloproliferative neoplasms clinical trials in Kansas City, KS. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
76
Enrolling

Recruiting Myeloproliferative Neoplasms Studies in Kansas City

About Myeloproliferative Neoplasms Clinical Trials in Kansas City

Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.

There are currently 1 myeloproliferative neoplasms clinical trials recruiting participants in Kansas City, KS. These studies are seeking a combined 76 participants. Research is being sponsored by Ajax Therapeutics, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myeloproliferative Neoplasms Clinical Trials in Kansas City — FAQ

Are there myeloproliferative neoplasms clinical trials in Kansas City?

Yes, there are 1 myeloproliferative neoplasms clinical trials currently recruiting in Kansas City, KS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Kansas City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.

Are clinical trials in Kansas City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.

What myeloproliferative neoplasms treatments are being tested?

The 1 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.

Data updated July 13, 2026 from ClinicalTrials.gov